Trialist Concerns
- Major Trial Questions
- Time Investment
- Rewards

Patient Concerns
- Privacy
- Want Data to be Widely but Responsibly Used

Data Scientists Concerns
- Transparency
- Data Not Public
- New Ideas

Advancing Human Health
Sprint Trial Timeline...
A Randomized Trial of Intensive versus Standard Blood-Pressure Control

The SPRINT Research Group*
≥ 50 years
SBP 130–180 mmHg
↑ CV Risk
<120 mm Hg (Intensive)  <140 mm Hg (Standard)

9361 patients
Composite Cardiovascular Events (% per yr)

Intensive: 16 cases per 1000
Standard: 21 cases per 1000

Based on data available as of 11/6/2015
Don’t Delay News of Medical Breakthroughs

By ERIC J. TOPOL and HARLAN M. KRUMHOLZ  SEPTEMBER 17, 2015
Challenge Entries and Winners

Boston University
The role of renal impairment on outcome
2nd place

Stanford University
A risk score in quartiles
3rd place

Clalit Research Institute
A patient-physician friendly risk calculator
1st place
A Randomized Trial of Intensive versus Standard Blood-Pressure Control

The SPRINT Research Group

![Graph showing blood pressure levels over time for standard and intensive treatment groups.](image)

<table>
<thead>
<tr>
<th>Years</th>
<th>Standard Treatment</th>
<th>Intensive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>145</td>
<td>145</td>
</tr>
<tr>
<td>5</td>
<td>150</td>
<td>140</td>
</tr>
</tbody>
</table>

**Figure 2. Systolic Blood Pressure in the Two Treatment Groups over the Course of the Trial.**

The systolic blood-pressure target in the intensive-treatment group was less than 120 mm Hg, and the target in the standard-treatment group was less than 140 mm Hg. The mean number of medications is the number of blood-pressure medications administered at the exit of each visit. Bars represent 95% confidence intervals.